• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Karen Ignagni Calls for Greater Transparency in Pharmaceutical Pricing

Video

No entity in healthcare should have a blank check, but that's the current situation with specialty drugs, said Karen Ignagni, president and chief executive officer of America's Health Insurance Plans.

No entity in healthcare should have a blank check, but that’s the current situation with specialty drugs, said Karen Ignagni, president and chief executive officer of America’s Health Insurance Plans.

Her association has been trying to create a dialogue with pharmaceutical companies to find a way for greater transparency in pricing.

“We want to create sustainable innovation,” she said. “There’s no question. Every American wants that. But at the same time we’re not going to be able to create sustainable innovation unless we have such sustainable pricing.”

Related Videos
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center (UPMC)
Pierluigi Porcu, MD
Benjamin Chen, MD, PhD
Kimberly Westrich, MA, chief strategy officer, NPC
Erin Weber, MS
JC Scott, CEO and president of The Pharmaceutical Care Management Association (PCMA)
Marla Black Morgan, MD, Phoebe Neurology Associates
Elizabeth Grush, MBA
Raj Chovatiya, MD, PhD, MSCI.
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.